Our Founder and CEO, Su Metcalfe, will join Lord Bilimoria, British Indian entrepreneur and a life peer, at the House of Lords for the All-Party Parliamentary Group (APPG) for Entrepreneurship launch of a report on Enterprise Education at Universities on Nov 14th 2018.Read More
LIFNano's Su Metcalfe is joining global opinion leaders in MS who will be presenting latest advances in MS management and treatment. The meeting is to be Chaired by Professor Gavin Giovannoni (London; member of LIFNano's Advisoory Board) and William Carroll (Perth Australia).Read More
On October 17th, LIFNano's President Su Metcalfe is honored to be joining CAMBRIDGE'S MOST INFLUENTIAL BUSINESS'S by kind invitation of Cambridge News and Media. An excellent opportunity to engage on behalf of our wider community of supporters and MS'ers"
At the upcoming International Meeting in Munich, Su Metcalfe will be presenting the unique properties of LIFNano for treatment of MS, including successful delivery of LIFNano across the blood-brain barrier. 4th Annual Neuroscience R&D Technologies Conference 4th -5th October 2018 Munich Germany.
We are delighted to welcome Andrew Carver who brings experience in the development and cGMP manufacture of recombinant therapeutic biologics.
Following kind invitation from The Rt Hon Liam Byrne MP and Baroness Kramer, our founder Dr Su Metcalfe will attend the launch of three Government briefing papers, including Women in Leadership, at the House of Lords.Read More
Our vision for the first clinical trial in multiple sclerosis is on course for 2020, supported by a UK government funding award.Read More
If you are not already familiar with it, we would like to draw your attention to the UK MS Register.Read More
In November in Berlin, we were delighted to receive the GLOBAL AWARD FOR NANOMEDICINE 2017, a highly prestigious prize.Read More
We are deeply saddened to hear of the death of Terry Strom, pioneering clinical transplant immunologist who worked with our Founder in the discovery of LIF's role in immune self-tolerance.Read More